Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.

By O. Wazni, N. Marrouche, David O. Martin, A. Verma, M. Bhargava, W. Saliba, Dianna Bash, Robert A. Schweikert, J. Brachmann, J. Gunther and 9 more. Journal of the American Medical Association (JAMA), 2005

1,169 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/246ab3deccc5928ca8c2fa9167711e12c336881f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. M. Ezekowitz
2. Stanley Nattel
3. Gerhard Hindricks

Citations in the corpus

• Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. (2010, background): “Major adverse events have been reported in up to 6% of patients undergoing AF ablation, including thromboembolic events, atrialesophageal fistula, cardiac perforation, phrenic nerve paralysis, and death.(12-16,24) None of these more serious complications occurred in our study.”
• 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “catheter ablation compared to antiarrhythmic drug therapy with or without cardioversion (Web Figure 2).(185,717,723) – 726,1039 In patients who experience symptomatic recurrences of AF despite antiarrhythmic drug therapy, all RCTs showed better sinus rhythm maintenance with catheter ablation than on”
• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. (2012, result): “Similar information has emerged from the results of the RAAFT II (Radiofrequency Ablation for Atrial Fibrillation Trial).(158)”
• 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation (2017, background): “More important are the results of randomized clinical trials that compared catheter ablation with AAD therapy in patients with PAF, and evaluated QOL as an outcome measure.(261,377,378,379,684)”